THP	B-Chemical
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
,	O
reducing	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
and	O
reducing	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
in	O
mice	O
.	O

Interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
:	O
case	O
series	O
.	O

Differential	O
effects	O
of	O
gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
(	O
lindane	B-Chemical
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	B-Disease
.	O

Pneumonitis	O
with	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusion	I-Disease
and	O
neuropathy	B-Disease
during	O
amiodarone	B-Chemical
therapy	O
.	O

A	O
deficient	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
-	O
nitric	B-Chemical
oxide	I-Chemical
system	O
is	O
implicated	O
in	O
cortisol	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	B-Chemical
.	O

Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	B-Chemical
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
clones	O
.	O

Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O

Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	B-Disease
,	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
,	O
VPA	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
and	O
VPA	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
.	O

Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	B-Chemical
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video	O
-	O
oculography	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O

The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O

Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-Chemical
vasopressin	I-Chemical
nor	O
oxytocin	B-Chemical
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O

Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	B-Chemical
(	O
epinephrine	B-Chemical
)	O
,	O
atropine	B-Chemical
and	O
furosemide	B-Chemical
was	O
successful	O
.	O

Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	B-Disease
are	O
briefly	O
discussed	O
.	O

Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	B-Chemical
-	O
drug	O
interaction	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-Disease
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	B-Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
treatment	O
with	O
CC	B-Chemical
.	O

Terbutaline	B-Chemical
,	O
a	O
beta2	O
-	O
adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	B-Disease
labor	I-Disease
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	B-Disease
in	O
dizygotic	O
twins	O
.	O

Five	O
patients	O
with	O
carcinoma	B-Disease
developed	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
characterized	O
by	O
renal	B-Disease
insufficiency	I-Disease
,	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
usually	O
thrombocytopenia	B-Disease
)	O
after	O
treatment	O
with	O
cisplatin	B-Chemical
,	O
bleomycin	B-Chemical
,	O
and	O
a	O
vinca	B-Chemical
alkaloid	I-Chemical
.	O

Ten	O
patients	O
with	O
PD	B-Disease
and	O
prominent	O
dyskinesias	B-Disease
had	O
rTMS	O
(	O
1	O
,	O
800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	B-Chemical
directly	O
causes	O
increased	O
glomerular	O
permeability	O
/	O
injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O

The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
alone	O
increases	O
the	O
risk	O
of	O
ESRD	B-Disease
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	B-Chemical
139317	I-Chemical
on	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
was	O
studied	O
.	O

This	O
CAB	O
-	O
induced	O
anemia	B-Disease
was	O
normochromic	O
and	O
normocytic	O
.	O

These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	B-Chemical
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	B-Disease
-	O
associated	O
neuronal	B-Disease
damage	I-Disease
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O

The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	B-Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	B-Disease
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O

Beyond	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O

A	O
frequency	O
of	O
bradycardia	B-Disease
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	B-Chemical
.	O

In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	B-Chemical
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	B-Disease
.	O

CONCLUSIONS	O
:	O
Prilocaine	B-Chemical
may	O
be	O
preferable	O
to	O
lidocaine	B-Chemical
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	B-Disease
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	B-Disease
caused	O
by	O
injected	O
norepinephrine	B-Chemical
was	O
significantly	O
enhanced	O
by	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
,	O
DL	B-Chemical
-	I-Chemical
Threo	I-Chemical
-	I-Chemical
dihydroxyphenylserine	I-Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-Chemical
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Capecitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
dysfunctions	I-Disease
.	O

Intravenous	O
hydration	O
and	O
mannitol	B-Chemical
was	O
administered	O
before	O
and	O
after	O
cisplatin	B-Chemical
.	O

Lamivudine	B-Chemical
for	O
the	O
prevention	O
of	O
hepatitis	B-Disease
B	I-Disease
virus	O
reactivation	O
in	O
hepatitis	B-Chemical
-	I-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBSAG	B-Chemical
)	O
seropositive	O
cancer	B-Disease
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O

Vigabatrin	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O

